● TIER 2 — Compoundable · emerging dataGRADE BGH secretagogues & GH axis
Sermorelin
GHRH(1-29). Research verification: Yes (TGA pending). 1 human study record(s) in the FitClinicMD studies database.
GOALS · Muscle / body composition · Sleep
FDA status
Geref approved 1990s, withdrawn by sponsor (not for safety).
Compounding (503A/503B)
Compoundable under 503A as component of previously approved drug (not verified in this pass with FDA listing).
DEA
Not controlled.
WADA (sport)
S2.2.4 GH-releasing factors: GHRH & analogues (CJC-1295, sermorelin, tesamorelin), GHS (ibutamoren, ipamorelin), GHRPs (GHRP-2/6, hexarelin)
Mechanism
GHRH-R agonist, t½ minutes.
Human evidence · 1
Review of pediatric GHD use (BioDrugs 1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
Reference only. This page summarizes publicly available regulatory and research information about Sermorelin. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.